公开(公告)号：US20100254938A1

公开(公告)日：2010-10-07

申请号：US12755321

申请日：2010-04-06

申请人： Laura Ferro ,  Roberto Porta ,  Massimo Iacobelli ,  Massimo Alessandro Gianni ,  Carmelo Carlo Stella

发明人： Laura Ferro ,  Roberto Porta ,  Massimo Iacobelli ,  Massimo Alessandro Gianni ,  Carmelo Carlo Stella

IPC分类号： A61K38/19 ,  A61P7/00

CPC分类号： A61K31/7088 ,  A61K31/711 ,  A61K38/18 ,  A61K38/193 ,  A61K38/2053 ,  A61K31/70 ,  A61K2300/00

摘要： The present innovation relates to a novel formulation capable of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal; the formulation is characterised in that it contains defibrotide in combination with at least one haematopoietic factor having the capacity to mobilise haematopoietic progenitors, preferably G-CSF. In one embodiment, the formulation includes two separately administrable formulations, one containing a haematopoietic factor having the capacity to mobilize haematopoietic progenitors and the other containing defibrotide. The formulation is effective to achieve an increase in the number of haematopoietic progenitor cells that is greater than an increase in the number of haematopoietic progenitor cells achieved by the haematopoietic factor alone.

摘要翻译： 本发明涉及能够增加哺乳动物的外周血中循环中的干细胞和祖细胞的量的新型制剂; 该制剂的特征在于其含有脱铁肽与至少一种具有动员造血祖细胞，优选G-CSF的能力的造血因子组合。 在一个实施方案中，制剂包含两种可单独施用的制剂，一种含有能够动员造血祖细胞的造血因子，另一种含有脱铁肽。 该制剂有效地实现造血祖细胞的数量增加，其大于由造血因子单独实现的造血祖细胞数量的增加。

公开(公告)号：US08771663B2

公开(公告)日：2014-07-08

申请号：US12755321

申请日：2010-04-06

申请人： Laura Ferro ,  Roberto Porta ,  Massimo Iacobelli ,  Massimo Alessandro Gianni ,  Carmelo Carlo Stella

发明人： Laura Ferro ,  Roberto Porta ,  Massimo Iacobelli ,  Massimo Alessandro Gianni ,  Carmelo Carlo Stella

IPC分类号： A61K38/19

CPC分类号： A61K31/7088 ,  A61K31/711 ,  A61K38/18 ,  A61K38/193 ,  A61K38/2053 ,  A61K31/70 ,  A61K2300/00

摘要： The present innovation relates to a novel formulation capable of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal; the formulation is characterized in that it contains defibrotide in combination with at least one haematopoietic factor having the capacity to mobilize haematopoietic progenitors, preferably G-CSF. In one embodiment, the formulation includes two separately administrable formulations, one containing a haematopoietic factor having the capacity to mobilize haematopoietic progenitors and the other containing defibrotide. The formulation is effective to achieve an increase in the number of haematopoietic progenitor cells that is greater than an increase in the number of haematopoietic progenitor cells achieved by the haematopoietic factor alone.

摘要翻译： 本发明涉及能够增加哺乳动物的外周血中循环中的干细胞和祖细胞的量的新型制剂; 该制剂的特征在于其含有脱铁肽与至少一种具有动员造血祖细胞，优选G-CSF的能力的造血因子组合。 在一个实施方案中，制剂包含两种可单独施用的制剂，一种含有能够动员造血祖细胞的造血因子，另一种含有脱铁肽。 该制剂有效地实现造血祖细胞的数量增加，其大于由造血因子单独实现的造血祖细胞数量的增加。